Precigen Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PGEN Nasdaq 2836 https://precigen.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Precigen Inc

Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates - Mar 6th, 2023 9:05 pm
Precigen Is Pioneering a Nonsurgical Treatment for a Debilitating Respiratory Disease; Positive Data Released on Recurrent Respiratory Papillomatosis Showed a 50% Complete Response - Feb 7th, 2023 1:00 pm
Germantown's Precigen raises $75M to advance treatments for rare diseases - Jan 30th, 2023 7:34 pm
Precigen Announces Closing of Public Offering of Common Stock - Jan 27th, 2023 9:05 pm
Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock - Jan 25th, 2023 3:40 am
Precigen Announces Proposed $75.0 Million Public Offering of Common Stock - Jan 24th, 2023 9:05 pm
Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis - Jan 24th, 2023 9:01 pm
Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference - Jan 11th, 2023 11:45 pm
Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis - Jan 4th, 2023 9:05 pm
Precigen’s Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy - Dec 27th, 2022 1:00 pm
Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference - Dec 19th, 2022 9:05 pm
Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients - Dec 13th, 2022 12:01 am
Bullish: Analysts Just Made A Noticeable Upgrade To Their Precigen, Inc. (NASDAQ:PGEN) Forecasts - Nov 16th, 2022 10:07 am
Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs - Nov 9th, 2022 9:05 pm
Precigen to Announce Third Quarter 2022 Financial Results on November 9th - Nov 2nd, 2022 8:30 pm
Precigen Names Rutul R. Shah Chief Operating Officer - Sep 21st, 2022 8:30 pm
Precigen to Participate in the 2022 Wells Fargo Healthcare Conference - Sep 1st, 2022 12:05 pm
Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics - Aug 22nd, 2022 12:05 pm
Precigen Reports Second Quarter and First Half 2022 Financial Results - Aug 8th, 2022 8:05 pm
Investors in Precigen (NASDAQ:PGEN) from five years ago are still down 89%, even after 32% gain this past week - Aug 5th, 2022 12:36 pm